• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    CRISPR Therapeutics (CRSP) Could Be 33% Undervalued As Phase 1 Data Builds Pipeline Momentum

    Simply Wall St·11/10/2026 13:25:17
    Listen to the news

    CRISPR Therapeutics (CRSP) is back in focus after early trial readouts. New Phase 1 data for zugo cel in autoimmune disease and CTX310 in severe hypertriglyceridemia are giving investors fresh information on the pipeline.

    Those trial updates and the recent earnings release come against a share price that has softened in recent months, with CRISPR Therapeutics closing at US$50.04 and a 30 day share price return down 6.27% while the 1 year total shareholder return has declined 8.32%. Over a five year span, total shareholder return is down 41.18%, and the latest pipeline readouts and leadership change may be shifting how investors weigh long term opportunity against past volatility.

    Compare CRISPR Therapeutics' early trial momentum with a hand picked group of gene editing and biotech peers, screened for strong fundamentals and potential rerating using the 19 high quality undiscovered gems.

    CRISPR Therapeutics now pairs encouraging early data with a share price that has retreated over one year and five years. Is this still a strong platform that the market prices cautiously, or is it already a fully valued story?

    Most Popular Narrative: 33% Undervalued

    CRISPR Therapeutics last closed at $50.04, while the analyst consensus Narrative on Simply Wall St places fair value at about $74.33 using a 7.62% discount rate. That gap reflects a story built around multiple late stage assets rather than just CASGEVY.

    Expansion of CASGEVY to pediatric patients as young as 2 years old and a growing base of more than 75 authorized treatment centers worldwide increase the pool of eligible sickle cell and beta thalassemia patients. This can support higher future revenue and improve earnings leverage as fixed infrastructure is used more fully. Progression of CTX310 into later stage development following Phase 1a data that showed up to 80% ANGPTL3 reduction in the liver and around 50% LDL and triglyceride reductions for at least a year positions CRISPR Therapeutics to enter large cardiometabolic markets, which could add new revenue streams beyond CASGEVY.

    See why 17 investors see CRISPR Therapeutics as 33% undervalued.

    Result: Fair Value of $74.33 (UNDERVALUED)

    Still, the CRISPR Therapeutics story relies on expensive late stage trials and ongoing net losses. As a result, any setback in CASGEVY uptake or CTX310 progress could quickly challenge that undervaluation thesis.

    Find out about the key risks to this CRISPR Therapeutics narrative.

    Next Steps

    Does the CRISPR Therapeutics story feel cautious or optimistic to you right now? Act quickly, review the numbers, and weigh the 2 key rewards.

    Looking for more investment ideas beyond CRISPR Therapeutics?

    Do not stop with CRISPR Therapeutics alone. Broaden your watchlist using structured stock ideas that surface quality, value, and resilience across the market.